Tirzepatide vs Semaglutide: Which GLP-1 Is Right for Houston Patients?
Comparing tirzepatide (Zepbound) and semaglutide (Wegovy) for weight loss - clinical trial data, Houston-area costs, and how to choose with your physician.
Reviewed for accuracy against current FDA guidance, peer-reviewed clinical trial data (STEP, SURMOUNT trials), and manufacturer prescribing information. See our editorial standards.
Tirzepatide outperforms semaglutide in head-to-head clinical trials, but that single fact doesn't settle the question for most Houston patients weighing Zepbound against Wegovy. The two drugs work differently at the hormonal level, carry different side-effect profiles, and land at very different price points depending on whether you're going brand-name or compounded. Texas insurance coverage adds another layer — some plans in the Houston metro, including options common among employers in Sugar Land and The Woodlands, cover one but not the other. This article breaks down the clinical data, the real costs, and the practical factors Houston-area physicians use to match the right GLP-1 to the right patient.
1How Each Medication Works: GLP-1 vs. GIP + GLP-1
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the GLP-1 hormone your gut naturally releases after eating, signaling fullness to the brain, slowing digestion, and reducing calorie intake. Wegovy is the FDA-approved 2.4 mg once-weekly subcutaneous formulation specifically indicated for chronic weight management. Tirzepatide goes a step further. It is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist - often called a 'twincretin.' By activating both hormone receptors simultaneously, tirzepatide may produce stronger appetite suppression and greater improvements in metabolic markers than single-agonist therapies. Zepbound received FDA approval for chronic weight management in November 2023 at doses of 5 mg, 10 mg, and 15 mg, administered once weekly. Neither medication is a stimulant or appetite suppressant in the traditional sense. Both require a prescription, physician supervision, and are intended to complement - not replace - lifestyle modifications including nutrition changes and physical activity. Houston-area clinics typically pair both medications with structured behavioral counseling programs.
2Clinical Trial Data: STEP Trials vs. SURMOUNT Trials
The head-to-head evidence is compelling. In the STEP 1 trial (semaglutide 2.4 mg, n=1,961), participants achieved an average body weight reduction of approximately 14.9% over 68 weeks compared to 2.4% for placebo - a landmark result that established semaglutide as a best-in-class obesity treatment at the time of its approval. The SURMOUNT-1 trial (tirzepatide, n=2,539) published results showing average weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks vs. 3.1% for placebo. At the highest dose, roughly 1 in 3 participants lost 25% or more of their body weight - a threshold historically associated only with bariatric surgery outcomes. The SURMOUNT-2 trial, which enrolled patients with obesity and type 2 diabetes, found tirzepatide 15 mg produced approximately 15.7% weight loss vs. 3.3% for placebo over 72 weeks. Importantly, no large-scale, randomized, head-to-head trial between the two agents specifically designed for weight loss has been completed. Current superiority conclusions in clinical practice are drawn from cross-trial comparisons, which have inherent limitations. Houston physicians typically discuss these nuances during consultation.
3Side Effects and Tolerability: What Houston Patients Report
Both medications share a similar side-effect profile driven by their GLP-1 activity. The most commonly reported adverse events in clinical trials and real-world Houston clinic settings include nausea, vomiting, diarrhea, constipation, and decreased appetite - especially during the dose-escalation phase in the first 16–20 weeks of treatment. In STEP 1, approximately 44% of semaglutide participants reported nausea vs. 16% for placebo, with most cases rated mild to moderate. Discontinuation due to GI side effects occurred in about 4.5% of semaglutide participants. In SURMOUNT-1, GI side effects were similarly common with tirzepatide, with nausea reported in up to 31% of participants at 15 mg and discontinuation rates of approximately 6.2% at the highest dose. Both medications carry FDA black-box warnings regarding a potential risk of thyroid C-cell tumors observed in rodent studies; they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Houston-area physicians screen carefully for these contraindications before prescribing. Pancreatitis is a rare but serious risk requiring immediate evaluation if severe abdominal pain develops.
4Cost in Greater Houston: What to Budget in 2026
Medication cost is one of the most pressing concerns for Houston-area patients, and rightfully so. As of early 2026, the monthly list prices for both branded medications remain substantial: • Wegovy (semaglutide 2.4 mg, 4 pens): approximately $1,300–$1,450/month list price • Zepbound (tirzepatide, 4 pens): approximately $1,060–$1,300/month list price depending on dose Eli Lilly (Zepbound's manufacturer) has maintained a slightly lower list price than Novo Nordisk's Wegovy, and both companies offer manufacturer savings programs. Lilly's Zepbound Savings Card can reduce out-of-pocket costs to as low as $550/month for commercially insured patients who qualify, while Novo Nordisk's Wegovy savings program offers similar tiers. For uninsured or underinsured Houston patients, compounded semaglutide and tirzepatide have been available through 503B outsourcing facilities - however, the FDA has declared both reference drugs no longer in shortage as of early 2026, which significantly restricts the legal field for compounded versions. Houston patients should confirm current compounding regulations with their prescribing physician before pursuing this option, as the rules continue to evolve. Many independent Houston weight loss clinics offer bundled pricing that includes monthly physician visits, lab work, injection supplies, and medication management for $300–$600/month above medication cost.
5Texas Insurance Coverage: BCBSTX, Aetna, UnitedHealthcare & More
Texas insurance coverage for GLP-1 weight loss medications remains inconsistent and employer-plan-dependent - a reality that frustrates many Greater Houston patients. Here is a practical overview of the current options: • Blue Cross Blue Shield of Texas (BCBSTX): Coverage for Wegovy and Zepbound varies significantly by employer group plan. Individual and family marketplace plans generally do not cover weight loss medications under Texas ACA plans. Patients should request a prior authorization (PA) review and confirm their specific plan formulary. • Aetna: Some Aetna commercial plans in the Houston market cover Wegovy with step-therapy requirements (e.g., documented failure of prior weight loss attempts, BMI ≥30 or ≥27 with comorbidity). Zepbound coverage is plan-specific. • UnitedHealthcare: UHC has been among the more active payers in covering GLP-1 obesity medications for eligible commercial members, often with PA requirements including documented BMI criteria and physician attestation. • Texas Medicaid (STAR/CHIP): As of publication, Texas Medicaid does not routinely cover Wegovy or Zepbound for weight loss indications. Patients on Medicaid should discuss alternative obesity medicine strategies with their Houston physician. • Medicare Part D: The Inflation Reduction Act did not extend GLP-1 coverage for weight loss under Medicare Part D; coverage remains limited to diabetic indications under most plans. Always call the member services number on your insurance card and specifically ask about 'anti-obesity medications' or 'GLP-1 agonists for weight management' - terminology matters when Understanding prior authorization.
6Which Medication May Be Preferred: Patient Profiles to Discuss With Your Doctor
While only a board-certified physician can determine which medication is appropriate for you, the following patient profile considerations are commonly discussed at Houston-area obesity medicine clinics: Semaglutide (Wegovy) may be discussed first when: • A patient has established tolerability to GLP-1 therapy (e.g., previously on Ozempic for diabetes) • Insurance formulary favors semaglutide with lower copay tier • The patient's weight loss goal is moderate (10–15% body weight) and aligns with STEP trial outcomes • The treating physician prefers a longer post-approval safety record for this specific indication Tirzepatide (Zepbound) may be discussed first when: • Maximal weight loss efficacy is the primary clinical goal (e.g., BMI >40, or obesity with multiple comorbidities such as sleep apnea, hypertension, or prediabetes) • SURMOUNT trial data suggesting superior average weight loss at higher doses is clinically relevant for the patient • Cost comparison favors Zepbound after applying manufacturer savings programs • The patient has not previously responded adequately to GLP-1 monotherapy Both medications require the same foundational eligibility: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity, prescribed as part of a comprehensive, physician-supervised weight management program.
7Finding a Physician-Supervised Program in Greater Houston
Choosing the right medication is only part of the equation. Houston-area patients consistently report better long-term outcomes when GLP-1 therapy is delivered within a structured, physician-supervised program that includes regular follow-up, metabolic lab monitoring, dietary guidance, and behavioral support - rather than through telehealth-only or medication-only services. The Greater Houston metro offers a wide range of obesity medicine practices across its major suburbs. In The Woodlands and Cypress, several clinics specialize in comprehensive metabolic weight management with in-house dietitians. Katy and Sugar Land have seen significant growth in board-certified obesity medicine physicians (diplomates of the American Board of Obesity Medicine, ABOM) over the past three years. Pearland and the Clear Lake area similarly have expanding options for physician-supervised programs. When evaluating a Houston-area clinic, patients should ask: 1. Is the supervising physician ABOM-certified or fellowship-trained in obesity medicine? 2. Does the program include regular lab monitoring (metabolic panel, HbA1c, lipids)? 3. Is there a registered dietitian or certified health coach on the care team? 4. How are side effects and dose adjustments managed between visits? 5. What is the clinic's policy if a medication becomes unavailable or unaffordable? The Houston Weight Loss Directory lists clinics by suburb with verified physician credentials to help patients start their search.
8Key Questions to Ask at Your First Consultation
Walking into your first obesity medicine consultation in Houston - whether in Sugar Land, The Woodlands, or Midtown - prepared with the right questions can meaningfully change your outcome. Here are the most important ones to raise: • 'Based on my BMI, comorbidities, and labs, which medication do you recommend starting with, and why?' • 'What weight loss outcome is realistic for me over 6 and 12 months based on the clinical trial data?' • 'How will you manage my dose escalation schedule to minimize GI side effects?' • 'Will you submit a prior authorization to my insurance, and what documentation do you need from me?' • 'If my insurance denies coverage, what are my most affordable options - including manufacturer savings programs?' • 'What are the specific signs or symptoms that should prompt me to call the clinic between appointments?' • 'How long do most of your patients stay on GLP-1 therapy, and what happens to weight if they stop?' This last question is particularly important: clinical trial data from both the STEP and SURMOUNT programs show significant weight regain following medication discontinuation in the absence of continued lifestyle interventions - underscoring the chronic disease model of obesity management that evidence-based Houston physicians embrace.
Tirzepatide and semaglutide are both proven, FDA-approved tools in the fight against obesity - but they are not one-size-fits-all. The right choice depends on your clinical profile, goals, insurance plan, and budget. The physicians listed in the Houston Weight Loss Directory can guide you through a personalized evaluation. Browse clinics by suburb and schedule your consultation today to take the first evidence-based step toward lasting results.
Sources & References
Clinical data referenced in this article is drawn from the FDA drug database, peer-reviewed publications (STEP trials, SURMOUNT trials), and manufacturer prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro. Pricing figures reflect publicly available estimates and may vary. Insurance coverage information is general guidance — confirm your specific benefits with your plan.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any weight loss medication or program.